QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.102.042648v1 305/3/1173    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aleo, M. D. Articles by Kluwe, W. M. Search for Related Content PubMed PubMed Citation Articles by Aleo, M. D. Articles by Kluwe, W. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

TOXICOLOGY

Mechanism and Implications of Brown Adipose Tissue Proliferation in Rats and Monkeys Treated with the Thiazolidinedione Darglitazone, a Potent Peroxisome Proliferator-Activated Receptor- Agonist

Pfizer Global Research and Development, Drug Safety Evaluation (M.D.A., G.R.L., D.K.B., G.L.C., S.W.S., W.M.K.) and Drug Metabolism Department (W.M.S.), Groton, Connecticut

Thiazolidinediones represent an established class of insulin sensitizing agents for treating noninsulin-dependent diabetes mellitus. Darglitazone, a thiazolidinedione approximately 200x more potent than ciglitazone, was evaluated in preclinical safety assessment studies using rats (1, 5, and 50 mg/kg/day) and cynomolgus monkeys (50, 75, and 100 mg/kg/day). Darglitazone was a potent adipogenic agent in rats, causing hyperplastic/hypertrophic changes and firmness of white and perirenal, dorsal thoracic (TBAT), and interscapular brown adipose tissue (BAT). Progressive changes in BAT size, morphology, firmness, and fatty acid composition preceded clinical signs of impaired respiration and the subsequent development of a dose-dependent, life-threatening hydrothorax. The characteristics of the pleural effusate were consistent with lymphatic fluid. These adverse effects were ameliorated/reversed upon drug withdrawal and were insulin-dependent since rats rendered totally insulinopenic by streptozotocin pretreatment did not develop TBAT changes or hydrothorax. Although the effects of darglitazone on BAT changes were consistent with enhanced sensitivity to endogenous glucocorticoids, adrenalectomy, and dietary dehydroepiandrosterone administration were without a protective effect. Treated monkeys also developed white and BAT hyperplasia/hypertrophy, peripheral edema, and hydrothorax-related morbidity/mortality. Both species developed reversible, dose-related reductions in red blood cell parameters and follicular atresia. Peripheral and pulmonary edema are purportedly a multifactorial process involving vasodilatation, increased endothelial permeability, and/or plasma volume expansion due to reduced renal sodium excretion. Moreover, profound alterations in TBAT hypertrophy/hyperplasia/firmness may lead to discrete hydrothorax by restricting normal thoracic lymphatic drainage. Similar effects on adipose tissue, hemodilution, and edema (peripheral and pulmonary) were observed clinically with darglitazone and/or several other structurally similar/dissimilar PPAR- agonists.

Address correspondence to: Dr. Michael D. Aleo, Pfizer Global R & D, Groton Laboratories, Drug Safety Evaluation, MS 8274-1229, Eastern Point Rd., Groton, CT 06340. E-mail: michael_d_aleo{at}groton.pfizer.com

This article has been cited by other articles:

				G. J. Hausman, S. P. Poulos, T. D. Pringle, and M. J. Azain The influence of thiazolidinediones on adipogenesis in vitro and in vivo: Potential modifiers of intramuscular adipose tissue deposition in meat animals J Anim Sci, April 1, 2008; 86(14_suppl): E236 - E243. [Abstract] [Full Text] [PDF]

				M. D. Aleo, C. M. Doshna, and K. A. Navetta Ciglitazone-Induced Lenticular Opacities in Rats: In Vivo and Whole Lens Explant Culture Evaluation J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1027 - 1033. [Abstract] [Full Text] [PDF]

				Y. Rival, A. Stennevin, L. Puech, A. Rouquette, C. Cathala, F. Lestienne, E. Dupont-Passelaigue, J.-F. Patoiseau, T. Wurch, and D. Junquero Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor {gamma} Ligands J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 467 - 475. [Abstract] [Full Text] [PDF]

				T. P. Combs, U. B. Pajvani, A. H. Berg, Y. Lin, L. A. Jelicks, M. Laplante, A. R. Nawrocki, M. W. Rajala, Albert. F. Parlow, L. Cheeseboro, et al. A Transgenic Mouse with a Deletion in the Collagenous Domain of Adiponectin Displays Elevated Circulating Adiponectin and Improved Insulin Sensitivity Endocrinology, January 1, 2004; 145(1): 367 - 383. [Abstract] [Full Text] [PDF]